The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Employers have the opportunity to lead by example: to stop treating obesity as invisible and start addressing it as the ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

The first time around, 59-year-old James Brown lost a stone and a half when he took medication that aids weight loss. This ...

Swiss pharma giant Novartis is diving into research on ageing to tap the growing market for drugs that help keep older adults ...

Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Report from Canada’s Drug Agency says Wegovy cuts risk of heart attack, stroke or cardiovascular death by 20 per cent ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...